Format

Send to

Choose Destination
Int J Tuberc Lung Dis. 2017 Oct 1;21(10):1145-1149. doi: 10.5588/ijtld.16.0880.

Interferon-gamma response to the treatment of active pulmonary and extra-pulmonary tuberculosis.

Author information

1
Henan Provincial Chest Hospital, Zhengzhou, Henan.
2
Henan Public Health Clinical Center, Zhengzhou, Henan, China.
3
Clinical Monitoring Research Program, Clinical Research Directorate, Leidos Biomedical Research, Inc, Frederick, Maryland.
4
Tuberculosis Research Section, Laboratory of Clinical Infectious Diseases.
5
Biostatistics Research Branch, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland, USA.

Abstract

BACKGROUND:

Interferon-gamma (IFN-γ) release assays (IGRAs) are used to diagnose tuberculosis (TB) but not to measure treatment response.

OBJECTIVE:

To measure IFN-γ response to active anti-tuberculosis treatment.

DESIGN:

Patients from the Henan Provincial Chest Hospital, Henan, China, with TB symptoms and/or signs were enrolled into this prospective, observational cohort study and followed for 6 months of treatment, with blood and sputum samples collected at 0, 2, 4, 6, 8, 16 and 24 weeks. The QuantiFERON® TB-Gold assay was run on collected blood samples. Participants received a follow-up telephone call at 24 months to determine relapse status.

RESULTS:

Of the 152 TB patients enrolled, 135 were eligible for this analysis: 118 pulmonary (PTB) and 17 extra-pulmonary TB (EPTB) patients. IFN-γ levels declined significantly over time among all patients (P = 0.002), with this decline driven by PTB patients (P = 0.001), largely during the initial 8 weeks of treatment (P = 0.019). IFN-γ levels did not change among EPTB patients over time or against baseline culture or drug resistance status.

CONCLUSION:

After 6 months of effective anti-tuberculosis treatment, IFN-γ levels decreased significantly in PTB patients, largely over the initial 8 weeks of treatment. IFN-γ concentrations may offer some value for monitoring anti-tuberculosis treatment response among PTB patients.

PMID:
28911359
DOI:
10.5588/ijtld.16.0880
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Ingenta plc
Loading ...
Support Center